Genmab and Seattle Genetics has presented data from the innovaTV 204 phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer.
Patients had previously received a doublet chemotherapy and, if elig